Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Psoriatic arthritis
•
General Rheumatology
•
Dermatology
•
Primary Care
Would you continue TNF-inhibitor in a patient with psoriatic arthritis who has had multiple nonmelanoma skin cancers requiring Mohs surgery?
Related Questions
How do you approach managing nausea and GI side effects when initiating methotrexate?
Are there any concerns when combining apremilast with azathioprine?
How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?
